Jhpiego partners with ministries of health, multilateral and bilateral donors, Johns Hopkins University colleagues, international and local nongovernmental organizations, and communities to promote vaccine readiness, introduction, and scale-up, including generating demand and building community confidence in immunization.

Globally, we work on primary prevention of cervical cancer through HPV vaccination for adolescent girls. We have supported and are supporting the introduction of HPV vaccines in Côte d’Ivoire, India, Guinea, Liberia, Pakistan, the Philippines, and Zambia.

We also assist with the introduction of new malaria vaccines in high-prevalence countries. To date, we have worked with the ministries of health in Burkina Faso, Côte d’Ivoire, and Liberia and serve on the World Health Organization’s global malaria vaccine coordination group.

We help prepare the way for new products on the horizon, such as vaccines given late in pregnancy to protect newborns against respiratory syncytial virus (RSV) and improved vaccines against tuberculosis. We work in Kenya, Bangladesh, India, and elsewhere to understand how existing health facilities can be best prepared.

New vaccines play a key role in responding to global and regional health emergencies. We supported the rollout of COVID-19 vaccines in more than 15 countries and developed tools to promote the COVID-19 vaccine among pregnant women.

Jhpiego is a global leader in finding effective ways to combine immunization with other essential health services, a strategy known as integrated service delivery. For example, we’ve shown how immunization clinics for newborns can also provide valuable family planning support for mothers after childbirth.

We study how HPV vaccines for adolescent girls can be integrated with other youth health and welfare services. In Côte d’Ivoire, Nigeria, and Tanzania, we test practical solutions and also lead knowledge sharing efforts on this topic for eight additional countries. In Tanzania, we have supported the government in offering important health services for adolescents alongside HPV vaccinations at schools and health clinics.

In India and Tanzania, we demonstrated how HPV vaccination can be combined with youth health services. In these and other countries, Jhpiego uses human-centered design to ensure programs consider the needs of young people.

Jhpiego experts contribute to global advisory groups such as those supporting the World Health Organization and Gavi to examine how vaccines for older adolescents and adults could be made more accessible in low-income settings.

Jhpiego focuses on improving access to immunization for families and communities that are difficult to reach. This can include new approaches to reach zero-dose children who have not had the first essential vaccine, or to reach girls who are not in school with HPV vaccine.

Jhpiego supported Burkina Faso, the Democratic Republic of the Congo, Ghana, Liberia, Pakistan, Rwanda, Sierra Leone, and Zambia to develop successful applications for Gavi equity accelerator funding to reach zero-dose and under-vaccinated children. As a partner to the International Centre for Diarrhoeal Disease Research in Bangladesh, we work with the Country Learning Hub that is documenting new ways to reach families who are missing out on immunization.

We worked with the World Health Organization on global guidance to improve measles-rubella vaccine campaigns and supported catch-up efforts for HPV and other vaccines.

Through work funded by the US government, we helped respond to measles outbreaks in Tanzania and Côte d’Ivoire, helped strengthen routine immunization programs, and documented good practices in private-sector engagement to boost immunization programs’ reach and sustainability.

We work with technology companies to test new vaccination devices. For example, we researched needle-free jet injectors for the polio vaccine in Nigeria and new rapid diagnostics for measles in Zambia.